John H. JohnsonChief Executive Officer & Director
John H. Johnson is a recognized leader in the biopharmaceutical industry with more than three decades of experience. He was most recently the CEO of Strongbridge Biopharma plc prior to its acquisition by Xeris Biopharma Holdings. Mr. Johnson has held executive management roles at leading global corporations, including Johnson & Johnson, where he spent the majority of career. He served as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson, where he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses. Mr. Johnson also served as President of Eli Lilly & Company's Worldwide Oncology Unit, following the company's 2008 acquisition of ImClone Systems, Inc., where he served as CEO and a member of ImClone’s Board of Directors. John is also an experienced Director having served on numerous boards across industry, biotech, and biopharmaceutical services companies. Mr. Johnson is currently Chairman of Autolus Therapeutics (AUTL), and a Director of Xeris Biopharma Holdings, Inc. (XERS), Axogen (AXGN), and Verastem Oncology (VSTM). Mr. Johnson was also a Board member of BioAgilytix during Cobepa’s investment period.
Haiching Ma, PhDChief Scientific Officer
Dr. Ma joined Reaction Biology in 2001 as employee number one. He is the Chief Science Officer, where he developed and implemented the current Reaction Biology technology and service platforms. Dr. Ma is the Principal Investigator for multiple SBIR awards and an RO1 award from NIH all Reaction Biology totaling over $12 million, and which cover research topics including assay development for human kinome and epigenome targets, toxicity predictions, chemical microarray HTS and cell death prevention that reduce side effects from radiation therapies. Dr. Ma is serving as a national Steering Committee Member for the NIH National Cancer Institute's Chemical Biology Consortium. He received his Ph.D. in Pharmacology from the Medical School of The University of Pennsylvania and continued his postdoc training there in the Institute for Medicine and Engineering.
Sebastian Dempe, PhDChief Executive Officer Germany
Sebastian Dempe is biologist by training and received his doctorate degree from the German Cancer Research Center/ University of Heidelberg in 2010 where he was exploiting the capacity of parvovirus H1, currently tested in clinical studies, for the virotherapy of cancer using various preclinical research models. Starting his career in Business Development at ProQinase (2011-2014), he was later appointed as Executive Director Business Development of Crown Bioscience, Inc., leading the company’s European Business Development team until June 2019. Sebastian re-joined ProQinase as CEO/ Managing Director on July 01, 2019.
Emily DoyleChief People Officer
Emily Doyle brings more than 20 years of human resources, organizational development, and talent acquisition in the biopharmaceutical industry to Reaction. Ms. Doyle will help strengthen the Company’s dynamic culture of innovation and will be responsible for overseeing Reaction’s people strategy, including talent acquisition and administration, leadership development, compensation and benefits, and diversity and inclusion. Prior to joining Reaction, she was most recently Senior Vice President, Human Resources at Inzen Therapeutics, and previously served as Strongbridge BioPharma’s Chief Human Resource Officer and was responsible for talent development, culture building, and aligning internal communication and employee engagement strategy. Prior to joining Strongbridge in 2019, she held senior positions as Vice President of Global Human Resources at Globus Medical Inc., and Head of HR for AstraZeneca’s diabetes franchise. She held progressively responsible roles in HR, sales, and commercial learning at Shire Pharmaceuticals before joining AstraZeneca. Emily holds a BS in healthcare management from Metropolitan State University of Denver and is pursuing an MBA from LaSalle University.
Alan FindlaterChief Commercial Officer
Alan Findlater brings more than 25 years of senior commercial and global marketing leadership in the life sciences, drug discovery, pharmaceutical, and medical device industries to Reaction. In this new role, Mr. Findlater will help to drive and support the Company’s strategic commercial objectives, integrated commercial architecture, and oversee the business development, client services, and sales functions. Prior to joining Reaction, Mr. Findlater was most recently CCO of BioIVT, responsible for building the global commercial strategy and leading global sales, marketing, and commercial services teams in the US, Europe, and Asia Pacific. He also previously served as CCO at Vium Inc., Executive Director, Global Business Development and Safety Assessment, Discovery, and Research Models and Executive Director, Corporate Development at Charles River Laboratories, and as CCO at WIL Research Laboratories. He has served in many senior leadership roles in sales, client services, and business development through the course of his career and has extensive experience representing multiple global life sciences products and services at dispersed sites, commercial leadership of M&A programs, strategic partnership building, and global commercial and marketing team leadership. Earlier in his career, Mr. Findlater held roles of increasing seniority in the areas of early pharmaceutical development and global clinical pharmacology at leading organizations such as Covance Laboratories, Johnson & Johnson (Medical Device Division and at Ethicon) and Smith and Nephew Pharmaceuticals. Mr. Findlater holds an MBA from the University of Warwick Business School in the United Kingdom (UK), a diploma and certificate in marketing from the Chartered Institute of Marketing, UK, as well as a BS, Chemistry, from the University of Strathclyde, Glasgow, UK.
Robert Hartman, MSMEChief Information Officer
Robert Hartman joined Reaction Biology in 2009. Mr. Hartman developed and implemented the R-Net system, which converts unstructured laboratory documents into actionable data. This system drives automation, manages just-in-time inventory, performs statistical analysis, generates client and management reports, and serves as a job planning tool. Other systems designed and implemented at Reaction Biology by Mr. Hartman include database applications that integrate with client LIMS, software that converts client reports into neutral files or databases, and productivity tools that bi-directionally exchange data with client relationship management tools. Mr. Hartman has held the Director of Software Development role at several firms and has managed the development of several hundred commercial software development projects. Mr. Hartman holds a MS degree in Mechanical Engineering from Drexel University.
Richard S. KollenderChief Financial Officer & Chief Business Officer
Mr. Kollender has more than 30 years of experience in the healthcare industry. Prior to joining Reaction Biology, he served as Strongbridge BioPharma’s President and Chief Financial Officer and was responsible for strengthening the company’s financial position and footprint as a successful rare disease organization until it was acquired by Xeris Biopharma, Inc., in October 2021. From 2003, he served first as a Principal and then as Partner of Quaker Partners Management, LP, a healthcare investment firm. In addition, from August 2016 through September 2018, he served as Chief Business Officer and Chief Financial Officer of Rapid Micro Biosystems, a Quaker Partners’ portfolio company, where he played a key role in the business expansion and adoption of the company’s Growth Direct™ System. Previously, he held positions in sales, marketing, and worldwide business development at GlaxoSmithKline (GSK) and served as investment manager at its corporate venture capital arm, S.R. One. He began his career as a Certified Public Accountant, initially with KPMG. He currently serves as Chairman of the Board of Directors for Restorative Therapies. He also serves on the Board of Directors for Rapid Micro Biosystems (NASDAQ: RPID) and as an adjunct faculty member at Lehigh University. He previously served on the Board of Directors of Strongbridge BioPharma, Insmed, NuPathe, Inc., and Celator Pharmaceuticals, Inc., in addition to several other privately held companies. He holds an MBA and a certificate degree in the graduate program in health administration and policy, both from the University of Chicago and a B.A. in accounting from Franklin and Marshall College.
Goutham G. Reddy, JDGeneral Counsel
Mr. Reddy joined Reaction Biology as General Counsel in 2018, having been its corporate counsel since 2013. Prior to that, he was Corporate Counsel at Strategic Diagnostics and Senior Counsel at Cigna. Mr. Reddy oversees all legal affairs of Reaction Biology and its subsidiaries, in addition to assisting in M&A transactions. Mr. Reddy received his Doctor of Law degree from Case Western Reserve University School of Law. He also has a degree in biology from Kent State University.
Neena MaranoChief of Staff to the CEO
Neena Marano is an experienced client services, human resources, and operations professional and has been with Reaction Biology since 2014. Throughout her time with the Company, she has supported a diverse number of business functions, including marketing, customer service, IT, HR, recruiting, and facilities management. She most recently served as Associate Director, Business Operations & HR, where she planned, directed, and coordinated company-wide operations, facilitated business improvements, and worked closely with the EC and senior leadership teams. She also led the full recruiting and onboarding process for new employees. Prior to this role, she served as Business Operations Manager, where she worked to improve processes, streamline operations, increase productivity, and manage/support various departments, including HR and Client Service. Neena was previously in the role of Systems Administrator, where she worked directly with the CIO to manage technical support operations, train employees, and manage all computer networks. She has held roles of increasing seniority in the Marketing and Client Service group, responsible for staffing, training, and managing the group, executing marketing campaigns, and acting as a client service representative. Neena holds a Bachelor of Science degree in Biology from Bard College and is currently pursuing a Master of Business degree at West Chester University.
Eric S. Bodle, PhDVice President, Biochemistry
Dr. Bodle brings more than 16 years’ experience in the CRO industry. Dr. Bodle will help strengthen and develop the biochemistry organization’s processes and procedures allowing for continued growth while maintaining the highest quality science.
Prior to joining Reaction Biology, Dr. Bodle was the General Manager of Eurofins Agroscience Services, responsible for Eurofins’ largest environmental toxicology laboratory in the U.S. He also previously served as the Assistant Director of Analytical Chemistry and Formulation Sciences at WIL Research Laboratories.
Dr. Bodle holds a PhD in Analytical Chemistry from the University of Akron and an MBA from the University of Maryland Smith School of Business.
Kurumi Horiuchi, PhDSenior Director of Biochemistry, USA
Kurumi Horiuchi, PhD joined Reaction Biology in 2004. She is responsible for assay development and handles orders for custom biochemical assay development, including kinetic analysis for mechanism of action studies. Previously, she held positions as an enzymologist in the Enzymology Department at DuPont Merck, DuPont Pharmaceuticals, and Bristol-Myers Squibb, where she was involved in all stages of drug discovery, from target identification to clinical studies, including HTS, SAR, and mode of action studies for lead compounds. As an enzymologist, she focused specifically on difficult enzymes and problem compounds and developed assays for kinetic analyses in areas including cancer, inflammatory diseases, cardiovascular diseases, and antibacterial and antiviral therapies. Dr. Horiuchi holds a Ph.D. in Biophysics from the School of Science and Engineering at Waseda University. She completed postdoctoral training at the University of Pennsylvania, with a focus on smooth muscle regulation.
Bob Dougherty, PhDSenior Director of In Vitro Pharmacology, USA
Robert Dougherty, PhD joined Reaction Biology in 2018, bringing 30 years of pharmacology experience with an emphasis on cell-based drug discovery. Dr. Dougherty was previously Director of Discovery Biology for Jubilant Biosystems ion-channel group before it was acquired by Reaction Biology. Prior to that, he was the Director of Cellular Pharmacology for Amphora Discovery. He holds a Ph.D. in Pharmacology and Toxicology from Virginia Commonwealth University School of Medicine.
Ekaterina Kuznetsova, PhDSenior Director of Product Development, USA
Ekaterina Kuznetsova, PhD joined Reaction Biology in 2014 from Structure Genomic Foundation, with initial concentration on developing new assays and protein products for epigenetic targets, with all these years growing with Reaction Biology, she has lead the protein group and involving heavily in assay development both based on customer requests for special targets and internal R&D development plans. Under her leadership, Reaction Biology offers hundreds proteins for internal customer services and for customer researches, she made significant contributions in building Reaction Biology’s broad targets portfolios, and helped Reaction Biology to become one of the world leading CROs in drug discovery services for Epigenetic targets and the hot Ras pathways.
Michael Kubbutat, PhDHead of Biochemical Drug Discovery and Head of Drug Development, Germany
Michael Kubbutat studied biology and cell biology and obtained his Ph.D. at the Research Center Borstel, Germany. In 1994, Michael Kubbutat started post-doctoral studies at the Ludwig Institute for Cancer Research (London, UK) in the group of Prof. Karen Vousden. Together with the group of Prof. Vousden, he moved in 1995 to the National Cancer Institute, Frederick, USA. In 1999 he joined the Tumor Biology Center Freiburg, Germany first as a group leader (Molecular Cell Biology), and later as Head of the Target Identification & Validation Department. In 2001 he joined ProQinase as Head of R&D. Since 2010, Michael Kubbutat is Head of Biochemical Drug Discovery & Head of Drug Development at Reaction Biology Europe.
Holger Weber, PhDHead of In Vivo Pharmacology, Project Management & Internal Innovations
Holger Weber studied biology and obtained his Ph.D. at the Max-Planck Institute for Immunobiology in Freiburg, Germany. In 2001 he joined the research group of Prof. Augustin at the Tumor Biology Center, Freiburg. The scientific focus and interest during that time was the field of angiogenesis, first as a Post-Doc, later as a group leader. In 2007 he left basic research and started to work at ProQinase as a group leader in the Department of Cellular Drug Discovery. Since 2014, Holger Weber is Head of In Vivo Pharmacology responsible for the resorts Project Management and Internal Innovations.
Project Management & Animal Affairs
Cynthia Obodozie, DVM, PhDHead of In Vivo Pharmacology
Project Management & Animal Affairs
After completing her veterinary studies in Berlin, Germany, Cynthia wrote her doctoral thesis at the pharmaceutical company Bayer (formerly Schering AG, Berlin) in the preclinical oncology department in the field of antiestrogens and their anti-tumor effects on endometrial cancer. As a postdoc, Cynthia joined the research group of Prof. Augustin at the Tumor Biology Center, Freiburg, with a focus on tumor angiogenesis. Then she switched to ProQinase GmbH and worked as a senior scientist and later as a group leader in the in vivo pharmacology department. In the additional position as Head of Animal facility, she takes care of the concerns of the animals, the equipment, and the staff as well as the official regulations regarding animal studies. Since 2020, Cynthia Obodozie is Head of In Vivo Pharmacology responsible for the resorts Project Management and Animal Affairs.
Jan Ehlert, PhDHead of Cellular Drug Discovery, Germany
Jan Erik Ehlert is cell biologist by training and has gained his PhD at the Research Center Borstel, Germany, in the field of chemokine biology in innate immunology. During his Postdoc studies at the University of Michigan in Ann Arbor, he extended his scientific focus on the relevance of angiogenesis in lung cancer. In the year 2001, Jan Ehlert joined ProQinase as group leader in the field of target identification and validation in cancer biology. Since 2010, he is member of the management team at ProQinase as Head of the Department of Cellular Drug Discovery. His team is specialized on cellular assay systems in oncology, cellular screening and 3D assay systems. Jan Ehlert is co-inventor in several patents on compound classes issued to treat kinase-related cancer diseases.
Rebecca Eells, PhDDirector of Biophysics
Rebecca Eells, PhD joined RBC in 2018 and is the head of the biophysical assay services. Her group has developed and performed SPR projects for customers covering a large number of drug targets, involving broad range therapeutic areas, including cancer, antiviruses, etc. Dr. Eells has a broad background in biophysical assay development, specializing in SPR. She holds a Ph.D. in Molecular Biophysics and Structural Biology from Carnegie Mellon University.
Jianghong Wu, PhDDirector Of Cell Biology
Jianghong Wu, PhD joined RBC in 2012 and leads a team that performs kinase cell-based target engagement assays and other cell-based customer services. Dr. Wu has extensive experience in cell biology, molecular biology, and drug screening studies, and has over 20 years of research experience. He holds a Ph.D. degree in immunology from Nagoya University, Japan and did postdoctoral studies at the University of Toronto, and Thomas Jefferson University.
Safnas F. AbdulSalam, PhDDirector of Assay Development, USA
Safnas F. AbdulSalam joined Reaction Biology in 2019 and manages assay development activities from special customer requests and from internal research projects. She holds a PhD degree in Chemistry from University of Cincinnati, and postdoctoral training in Indiana University School of Medicine, where she optimized and executed high throughput screening assays to identify small molecule glycogen synthase inhibitors as potential therapeutics for glycogen storage disorders.
Charles Schmidt, PhDAssociate Director of Biophysics
Charles Schmidt, PhD joined RBC in 2021 as associate director of biophysics. He received his PhD in Biophysics from the University of Virginia with a background in protein structure determination by NMR and biophysical assay development. Following his graduate work, he held positions at Progenra, Inc. and LifeSensors, Inc., with a focus on SPR and TSA assay development and HTS centered on the ubiquitin-proteasome system.
Julian Wooltorton, PhDAssociate Director of In Vitro Safety
Julian Wooltorton joins us as the Associate Director of In Vitro Safety. He has a Ph.D. in Pharmacology from the University of London, UK and Merck Sharp & Dohme Neuroscience Research Centre. He has over 20 years of research experience and joins us from Delaware State University. Julian is a member of the electrophysiology group; he will be the key scientist to manage customer projects related to ion channels and in vitro toxicity tests.